Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01045356 · ClinicalTrials.gov registry record
Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass
A clinical trial, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 55
- Enrollment target
NCT01045356 is a clinical trial that has completed, run by Boston Children's Hospital. The registered enrollment target is 55 participants.
The verdict
NCT01045356 has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 55 participants
- Enrollment target
Study Summary
The purpose of this study is to measure blood levels of TXA in children having cardiac surgery which requires cardiopulmonary bypass. TXA is used to reduce bleeding during surgery. This study will help determine if the current dosing of TXA results in therapeutic blood levels.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2010-01 |
| Est. Completion | 2014-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01045356
The ClinicalTrials.gov registry entry for NCT01045356 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT01045356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01045356 about?
NCT01045356 is a clinical study titled "Pharmacokinetics of Tranexamic Acid (TXA) in Children Undergoing Repair of Congenital Heart Defects Utilizing Cardiopulmonary Bypass". The purpose of this study is to measure blood levels of TXA in children having cardiac surgery which requires cardiopulmonary bypass. TXA is used to reduce bleeding during surgery. This study will help determine if the current dosing of TXA results in therapeutic blood levels.
What is the current status of trial NCT01045356?
This trial is currently completed. The enrollment target is 55 participants. The study started on 2010-01. Estimated completion is 2014-12.
Who is sponsoring clinical trial NCT01045356?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.